These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 2068562

  • 1. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM, Sartori MT, Viero ML, Scapinello MP, Boeri G, Girolami A.
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
    Violi F, Ferro D, Alessandri C, Quintarelli C, Saliola M, Balsano F.
    Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
    [Abstract] [Full Text] [Related]

  • 3. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
    Cimminiello C, Milani M, Pietra A, Rossi F, Aloisio M, Nazzari M, Bonfardeci G.
    Semin Thromb Hemost; 1991 Apr; 17 Suppl 1():106-11. PubMed ID: 2068563
    [Abstract] [Full Text] [Related]

  • 4. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.
    Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F.
    Eur J Clin Pharmacol; 1988 Apr; 35(2):151-6. PubMed ID: 3191933
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON, Cizmeci G, Balkuv-Ulutin S.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Apr; 115(1-2):177-80. PubMed ID: 2459016
    [Abstract] [Full Text] [Related]

  • 6. The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance.
    Ulutin ON, Balkuv-Ulutin S, Ugur MS, Ulutin T, Ozsoy Y, Cizmeci G.
    Adv Exp Med Biol; 1990 Apr; 281():429-38. PubMed ID: 2102624
    [Abstract] [Full Text] [Related]

  • 7. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, Iacobelli M.
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [Abstract] [Full Text] [Related]

  • 8. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits.
    Löbel P, Schrör K.
    Atherosclerosis; 1989 Nov; 80(1):69-79. PubMed ID: 2513813
    [Abstract] [Full Text] [Related]

  • 9. Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.
    Violi F, Ferro D, Saliola M, Quintarelli C, Basili S, Balsano F.
    Eur J Clin Pharmacol; 1992 Nov; 42(4):379-83. PubMed ID: 1516602
    [Abstract] [Full Text] [Related]

  • 10. Defibrotide reduces monocyte PAI-2 and procoagulant activity.
    Abbate R, Gori AM, Martini F, Attanasio M, Comeglio P, Giusti B, Zarone N, Francalanci I, Prisco D, Gensini GF.
    Semin Thromb Hemost; 1995 Nov; 21(2):245-50. PubMed ID: 7660147
    [Abstract] [Full Text] [Related]

  • 11. Defibrotide therapy for thrombophlebitis--controlled clinical trial.
    Di Perri T, Vittoria A, Messa GL, Cappelli R.
    Haemostasis; 1986 Nov; 16 Suppl 1():42-7. PubMed ID: 3754835
    [Abstract] [Full Text] [Related]

  • 12. Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.
    Echart CL, Somaini S, Distaso M, Palumbo A, Richardson PG, Fareed J, Iacobelli M.
    Clin Appl Thromb Hemost; 2012 Nov; 18(1):79-86. PubMed ID: 21733935
    [Abstract] [Full Text] [Related]

  • 13. Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
    Ulutin ON.
    Semin Thromb Hemost; 1988 Nov; 14 Suppl():58-63. PubMed ID: 2848323
    [No Abstract] [Full Text] [Related]

  • 14. An integrated view of the activities of defibrotide.
    Pescador R, Porta R, Ferro L.
    Semin Thromb Hemost; 1996 Nov; 22 Suppl 1():71-5. PubMed ID: 8807733
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A, Fareed J, Sabbá C, Albano O, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Arpaia MR.
    Semin Thromb Hemost; 1991 Nov; 17 Suppl 2():228-34. PubMed ID: 1948094
    [Abstract] [Full Text] [Related]

  • 16. A novel insight into the mechanism of the antithrombotic action of defibrotide.
    Tettamanti R, Bianchi G, Vitte PA, Kato G, Porta R, Thiemermann C, Pescador R, Mantovani M.
    Life Sci; 1992 Nov; 51(19):1545-55. PubMed ID: 1331634
    [Abstract] [Full Text] [Related]

  • 17. Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit.
    Porta R, Calvani AB, Pescador R, Mantovani M, Prino G.
    Semin Thromb Hemost; 1991 Oct; 17(4):404-6. PubMed ID: 1803509
    [Abstract] [Full Text] [Related]

  • 18. Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers.
    Schoergenhofer C, Buchtele N, Gelbenegger G, Derhaschnig U, Firbas C, Kovacevic KD, Schwameis M, Wohlfarth P, Rabitsch W, Jilma B.
    Sci Rep; 2019 Jul 31; 9(1):11136. PubMed ID: 31366975
    [Abstract] [Full Text] [Related]

  • 19. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME.
    Vascul Pharmacol; 2013 Jul 31; 59(1-2):1-10. PubMed ID: 23680861
    [Abstract] [Full Text] [Related]

  • 20. Prophylaxis of venous thrombosis after gynaecological surgery: a controlled pilot study of defibrotide.
    Palareti G, Guazzaloca G, Legnani C, Leali N, Busacchi P, Sani G, Levorato M, Di Marco MG, Coccheri S.
    Haematologica; 1992 Jul 31; 77(1):44-8. PubMed ID: 1398281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.